In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immusol and NeoGenesis develop HIV drugs

Executive Summary

In a three-year deal, Immusol (ribozyme, antibody, and small-molecule products) and NeoGenesis Pharmaceuticals (chemical genomics and proteomics) will discover and develop small-molecule cellular drug candidates to treat HIV infection.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register